NMRA vs. HALO, KRYS, ADMA, ACLX, CRSP, IMVT, IBRX, DNLI, VCEL, and KYMR
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Arcellx (ACLX), CRISPR Therapeutics (CRSP), Immunovant (IMVT), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Vericel (VCEL), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics vs.
Neumora Therapeutics (NASDAQ:NMRA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
In the previous week, Halozyme Therapeutics had 13 more articles in the media than Neumora Therapeutics. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 12 mentions for Neumora Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.67 beat Neumora Therapeutics' score of -0.16 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Neumora Therapeutics has a beta of 3.92, meaning that its share price is 292% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Halozyme Therapeutics received 502 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.48% of users gave Neumora Therapeutics an outperform vote while only 69.47% of users gave Halozyme Therapeutics an outperform vote.
Halozyme Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a net margin of 41.43% compared to Neumora Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 179.82% beat Neumora Therapeutics' return on equity.
Neumora Therapeutics currently has a consensus target price of $21.67, suggesting a potential upside of 121.09%. Halozyme Therapeutics has a consensus target price of $61.11, suggesting a potential upside of 34.02%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Neumora Therapeutics is more favorable than Halozyme Therapeutics.
Summary
Halozyme Therapeutics beats Neumora Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NMRA) was last updated on 11/21/2024 by MarketBeat.com Staff
